A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas
Status: Not Recruiting
Patients diagnosed with unresectable pancreatic cancer who may or may not have had prior chemotherapy or radiation therapy may be eligible to enroll in this dose escalation study to determine the maximum tolerated dose of gemcitabine to be delivered locally to the pancreatic tumors using the RenovoCath R120 catheter. Although this drug and device are FDA approved, this trial is testing the two in combination for safety and efficacy.
For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.